ALK+ NSCLC
Oncology · 2013–2026
8decisions
5medicines
6carried consumer input
649individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alectinib Adjuvant therapy for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) after tumour resection in patients with tumours ≥4 cm or… | Mar 2026 | Recommended with restriction | no section in document |
| alectinib Adjuvant treatment in adult patients following tumour resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥4 cm… | May 2025 | Recommended with restriction | 9 individuals Medical Oncology Group · Rare Cancers Australia · Lung Foundation Australia · ALK Positive Australia |
| brigatinib Locally advanced (Stage IIIB) or metastatic (Stage IV) anaplastic lymphoma kinase (ALK)-positive non-squamous or not otherwise specified non-small cell lung… | Nov 2019 | Recommended with restriction | 70 individuals |
| lorlatinib Treatment of patients with metastatic (Stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), who have disease progression… | Nov 2019 | Recommended with restriction | 118 individuals |
| alectinib Treatment of patients with locally advanced (Stage IIIB) or metastatic (Stage IV) ALK-positive non-small cell lung cancer (NSCLC) who have disease progression… | Jul 2017 | Recommended with restriction | 173 individuals |
| ceritinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have… | Nov 2016 | Recommended with restriction | 18 individuals Rare Cancers Australia · Lung Foundation · Medical Oncology Group |
| crizotinib Treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) following disease… | Nov 2014 | Recommended with restriction | 261 individuals |
| crizotinib Second-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have disease progression… | Nov 2013 | Recommended with restriction | no section in document |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Lung Foundation Australia · ALK Positive Australia · Lung Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.